WO2009038412A3 - Beta-secretase inhibiting compounds - Google Patents

Beta-secretase inhibiting compounds Download PDF

Info

Publication number
WO2009038412A3
WO2009038412A3 PCT/KR2008/005593 KR2008005593W WO2009038412A3 WO 2009038412 A3 WO2009038412 A3 WO 2009038412A3 KR 2008005593 W KR2008005593 W KR 2008005593W WO 2009038412 A3 WO2009038412 A3 WO 2009038412A3
Authority
WO
WIPO (PCT)
Prior art keywords
beta
inhibiting compounds
secretase inhibiting
secretase
isomers
Prior art date
Application number
PCT/KR2008/005593
Other languages
French (fr)
Other versions
WO2009038412A2 (en
Inventor
Hyo-Shin Kwak
Ki Dong Koo
Dongchul Lim
Kyeongsik Min
Heuisul Park
Deog-Young Choi
Jae-Ung Choi
Hyunjung Park
Mijeong Park
Original Assignee
Lg Life Sciences Ltd
Hyo-Shin Kwak
Ki Dong Koo
Dongchul Lim
Kyeongsik Min
Heuisul Park
Deog-Young Choi
Jae-Ung Choi
Hyunjung Park
Mijeong Park
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Life Sciences Ltd, Hyo-Shin Kwak, Ki Dong Koo, Dongchul Lim, Kyeongsik Min, Heuisul Park, Deog-Young Choi, Jae-Ung Choi, Hyunjung Park, Mijeong Park filed Critical Lg Life Sciences Ltd
Publication of WO2009038412A2 publication Critical patent/WO2009038412A2/en
Publication of WO2009038412A3 publication Critical patent/WO2009038412A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms

Abstract

Disclosed are compounds represented by Formula (I) as defined in the specification, or pharmaceutically acceptable salts or isomers thereof, and a pharmaceutical composition for inhibiting beta-secretase activity comprising a therapeutically effective amount of the same.
PCT/KR2008/005593 2007-09-21 2008-09-22 Beta-secretase inhibiting compounds WO2009038412A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2007-0096584 2007-09-21
KR20070096584 2007-09-21

Publications (2)

Publication Number Publication Date
WO2009038412A2 WO2009038412A2 (en) 2009-03-26
WO2009038412A3 true WO2009038412A3 (en) 2009-05-07

Family

ID=40468635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/005593 WO2009038412A2 (en) 2007-09-21 2008-09-22 Beta-secretase inhibiting compounds

Country Status (2)

Country Link
KR (1) KR20090031333A (en)
WO (1) WO2009038412A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2865504T3 (en) 2008-10-16 2021-10-15 Univ Johns Hopkins Procedures and compositions for the improvement of cognitive function
AU2011209274B8 (en) 2010-01-29 2015-08-13 Boehringer Ingelheim International Gmbh Substituted naphthyridines and their use as Syk kinase inhibitors
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
DE102014110782A1 (en) * 2014-07-30 2016-02-04 Eberhard Karls Universität Tübingen Medizinische Fakultät Preparation of pyrrolidine derivatives
EA034167B8 (en) 2015-05-22 2021-04-27 Эйджинбайо, Инк. Extended release pharmaceutical compositions of levetiracetam
WO2022200208A1 (en) 2021-03-22 2022-09-29 Bayer Aktiengesellschaft Substituted pyrrolidin-2-ones, salts thereof and their use as herbicidally active substances
WO2022268520A1 (en) 2021-06-21 2022-12-29 Bayer Aktiengesellschaft Use of substituted pyrrolidinones or their salts for increasing stress tolerance of plants

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006021A1 (en) * 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Alpha-hydroxyamide statine derivatives for the treatment of alzh eimer's disease
US20040171881A1 (en) * 2001-11-08 2004-09-02 Varghese John N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives
WO2005087215A1 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
WO2007047306A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003006021A1 (en) * 2001-07-10 2003-01-23 Elan Pharmaceuticals, Inc. Alpha-hydroxyamide statine derivatives for the treatment of alzh eimer's disease
US20040171881A1 (en) * 2001-11-08 2004-09-02 Varghese John N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives
WO2005087215A1 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
WO2007047306A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors

Also Published As

Publication number Publication date
KR20090031333A (en) 2009-03-25
WO2009038412A2 (en) 2009-03-26

Similar Documents

Publication Publication Date Title
WO2009038412A3 (en) Beta-secretase inhibiting compounds
WO2009010416A3 (en) Inhibitors of 11b-hydroxysteroid dehydrogenase
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2007135527A3 (en) Benzimidazolyl compounds
WO2007107470A3 (en) Pyrazoles as 11-beta-hsd-1
GEP20135803B (en) Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
WO2009155121A3 (en) Inhibitors of pi3 kinase
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
WO2007060140A3 (en) Inhibitors of diacyglycerol acyltransferase (dgat)
GEP20125624B (en) Pyridazine derivatives as smo inhibitors
WO2008096001A8 (en) Hcv inhibiting macrocyclic phenylcarbamates
WO2007084728A3 (en) 2-imino-benzimidazoles
EP2639229A3 (en) Thiazole Derivative and use thereof as VAP-1 Inhibitor
WO2007126900A3 (en) Antifungal agents
WO2010098600A3 (en) Substituted azole derivatives, pharmaceutical composition containing the derivatives, and method for treating parkinson's disease using the same
WO2008006795A3 (en) Indole compounds
WO2006127379A3 (en) Par2-modulating compounds and their use
WO2008008660A3 (en) Cyclopentane derivatives as antiglaucoma agents
WO2008143649A3 (en) Novel oxazolidinone compounds as antiinfective agents
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2009051223A1 (en) Pharmaceutical composition for treatment of cataract
WO2009145591A3 (en) Phenyl piperazine compounds, pharmaceutical composition including the same, and use thereof
WO2012140596A8 (en) Glycoside derivatives and uses thereof
WO2007112913A3 (en) Benzimidazole derivatives

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08832439

Country of ref document: EP

Kind code of ref document: A2

DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08832439

Country of ref document: EP

Kind code of ref document: A2